Preclinical Evaluation of a PSMA Aptamer-Based Bifunctional PET and Fluorescent Probe
Bioconjugate Chemistry · 2024
DOI: 10.1021/acs.bioconjchem.4c00292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Sudong Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorescent Dyes, Prostatic Neoplasms, Aptamers, Nucleotide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Jiangsu Commission of Health, Science Technology and Development Project of Wuxi.
Abstract (Originalsprache)
Prostate cancer is the most prevalent malignant tumor affecting male individuals worldwide. The accurate early detection of prostate cancer is crucial to preventing unnecessary diagnosis and subsequent excessive treatment. Prostate-specific membrane antigen (PSMA) has emerged as a promising biomarker for the diagnosis of prostate cancer. In this study, a dual-modality imaging probe utilizing aptamer technology was developed for positron emission tomography/near-infrared fluorescence (PET/NIRF) imaging, and the specificity and sensitivity of the probe toward PSMA were evaluated both in vitro and in vivo. The probe precursor NOTA-PSMA-Cy5 was synthesized via automated solid-phase oligonucleotide synthesis. Subsequently, the PET/NIRF dual-modality probe [68Ga]Ga-NOTA-PSMA-Cy5 was successfully prepared and exhibited favorable fluorescence properties and stability in vitro. The binding specificity of [68Ga]Ga-NOTA-PSMA-Cy5 to PSMA was assessed through flow cytometry, fluorescence imaging, and cellular uptake experiments in LNCaP cells and PC-3 cells. In vivo PET/NIRF imaging studies demonstrated the sensitive and specific binding of [68Ga]Ga-NOTA-PSMA-Cy5 to PSMA. Overall, the PET/NIRF dual-modality probe [68Ga]Ga-NOTA-PSMA-Cy5 shows promise for the diagnosis of prostate cancer and for the fluorescence-guided identification of PSMA-positive cancer lesions during surgical procedures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, China.
- NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
- Suzhou Biosyntech Co., Ltd., Suzhou 215300, China.
ORCID-Profile: Jianguo Lin
Förderung
- Jiangsu Commission of Health
- Science Technology and Development Project of Wuxi
Zitieren
APA
Kong, S., Peng, Y., Liu, Q., Xie, Q., Qiu, L., Lin, J., & Xie, M. (2024). Preclinical Evaluation of a PSMA Aptamer-Based Bifunctional PET and Fluorescent Probe. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00292
Vancouver
Kong S, Peng Y, Liu Q, Xie Q, Qiu L, Lin J, et al. Preclinical Evaluation of a PSMA Aptamer-Based Bifunctional PET and Fluorescent Probe. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00292
BibTeX
@article{Kong2024,
author = {Kong, Sudong and Peng, Ying and Liu, Qingzhu and Xie, Quan and Qiu, Ling and Lin, Jianguo and Xie, Minhao},
title = {Preclinical Evaluation of a PSMA Aptamer-Based Bifunctional PET and Fluorescent Probe},
journal = {Bioconjugate Chemistry},
year = {2024},
doi = {10.1021/acs.bioconjchem.4c00292}
}
EUVIMED